WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

Saved in:

Bibliographic Details
Main Authors:	Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, Richard A. Lafayette, Adeera Levin, Adrian Liew, Hong Zhang, Todd Gray, Khushboo Sheth, Marianne Camargo, Ronny Renfurm, Andrew King, Jonathan Barratt
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924004649
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01)

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]
by: Hiddo J.L. Heerspink, et al.
Published: (2025-04-01)

WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
by: Irene L. Noronha, et al.
Published: (2024-04-01)

WCN25-1638 ALIGN SUBGROUP ANALYSES: CLINICALLY MEANINGFUL UPCR REDUCTIONS SEEN ACROSS SUBGROUPS
by: Meg Jardine, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK
by: Sradha Kotwal, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
by: Jonathan Barratt, et al.
Published: (2025-02-01)

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts
by: Sean J. Barbour, et al.
Published: (2025-04-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Sex Inequities in Clinical Trials and Trial Leadership
by: Anna Francis, et al.
Published: (2024-04-01)

Erratum to “Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287]
by: Sean J. Barbour, et al.
Published: (2025-07-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial
by: Akihiko Koshino, et al.
Published: (2024-02-01)

WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY
by: Richard Lafayette, et al.
Published: (2025-02-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

Assessing the potential causal effects of 1099 plasma metabolites on 2099 binary disease endpoints
by: Xianyong Yin, et al.
Published: (2025-03-01)

Modeling the surface mass balance of Penny Ice Cap, Baffin Island, 1959–2099
by: Nicole Schaffer, et al.
Published: (2023-09-01)

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
by: Howard Trachtman, et al.
Published: (2024-04-01)

WCN24-1550 ALDOSTERONE SYNTHASE INHIBITION WITH OR WITHOUT BACKGROUND SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION IN CKD: A PHASE II CLINICAL TRIAL
by: Katherine Tuttle, et al.
Published: (2024-04-01)

Trends in Dryness Index Based on Potential Evapotranspiration and Precipitation over 1961–2099 in Xinjiang, China
by: Yi Li, et al.
Published: (2014-01-01)

Modeling the surface mass balance of Penny Ice Cap, Baffin Island, 1959–2099 – CORRIGENDUM
by: Nicole Schaffer, et al.
Published: (2025-01-01)

Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial
by: Lihua Wang, et al.
Published: (2025-04-01)

Projection of the UV Radiation for Vitamin D Production Changes Between 2015–2024 and 2090–2099 Periods
by: Vladimir Zubov, et al.
Published: (2025-06-01)

Mass balance of IGAN Glacier (the Polar Urals) in 2018–2023
by: G. A. Nosenko, et al.
Published: (2025-02-01)

Analysis of the Fatigue Damage Behavior of AW2099-T83 Al-Li Alloy under Strain-Controlled Fatigue
by: Muhammed Jamiu Adinoyi, et al.
Published: (2019-06-01)

Design and Baseline Evaluation of Social Media Vaping Prevention Trial: Randomized Controlled Trial Study
by: William Douglas Evans, et al.
Published: (2025-03-01)

Spatiotemporal variation of snowpack depths in Northeast China and its mechanisms from 2025 to 2099 based on CMIP6 models
by: Cheng Xiyao, et al.
Published: (2025-02-01)

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE Study
by: Charles L. Daley, et al.
Published: (2025-04-01)

WCN24-1980 Efficacy and safety of zibotentan in combination with dapagliflozin in patients with CKD according to baseline diabetes status and kidney function
by: Hiddo Lambers Heerspink, et al.
Published: (2024-04-01)

Glaucoma Trials Simplified
by: Arshi Singh, et al.
Published: (2023-04-01)